| Characteristics |
n |
|
| Gender, n (%) of male |
364 |
293 (81) |
| Mean age (SD), years |
358 |
45 (9) |
| Mean weight (SD), kg |
361 |
65 (13) |
| HIV transmission, n (%) |
|
|
| Sexual |
364 |
281 (77) |
| Drug addiction |
364 |
53 (15) |
| Blood transfusion or blood exposure accidents |
364 |
13 (4) |
| Other or unknown |
364 |
17 (5) |
| CDC stage C, n (%) |
362 |
189 (52) |
| HBV coinfection (HBsAg), n (%) |
364 |
15 (4) |
| HCV coinfection (anti-HCV), n (%) |
364 |
60 (17) |
| Mean (SD) delay since HIV infection diagnosis, years |
266 |
15 (4) |
| Median (range) number of prior antiretroviral drugs |
352 |
11 (1–21) |
| Median (range) CD4 cells/mm3 |
338 |
155 (1–937) |
| < 200 cells/mm3, n (%) |
338 |
207 (61) |
| ≥ 200 cells/mm3, n (%) |
338 |
131 (39) |
| Median (range) HIV-1 RNA, log10 copies/mL |
333 |
4.7 (1.3–6.5) |
| Genotypic sensitivity score, n (%)* |
|
|
| 0 |
327 |
49 (15) |
| 1 |
327 |
129 (39) |
| 2 |
327 |
125 (38) |
| 3 |
327 |
22 (7) |
| 4 |
327 |
2 (1) |
*The number of active antiretroviral molecules was assessed in 327 patients with
genotypes available at inclusion (3TC/FTC was not taken into account). |
